FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094973399> ?p ?o ?g. }

• W2094973399 endingPage "250" @default.
• W2094973399 startingPage "246" @default.
• W2094973399 abstract "Thalidomide is effective for the treatment of severe cutaneous lupus. Our aim was to study the safety and efficacy of different doses of thalidomide in this condition.We studied patients with severe cutaneous lupus that was unresponsive to antimalarials, prednisolone, methotrexate, azathioprine, and cyclosporin A. Starting doses of 100 mg daily (n = 16 patients), 50 mg daily (n = 17), or 50 mg on alternate days (n = 15) were compared. The response to thalidomide was categorized as complete remission, partial remission, or no visible improvement. All patients received a baseline electromyogram (EMG) followed by repeat EMG every 3 to 6 months, or sooner if neuropathic symptoms developed.Forty-eight patients (46 female; mean [+/- SD] age, 44 +/- 12 years; range, 22 to 71 years) with discoid lupus (n = 18), subacute cutaneous lupus (n = 6), or systemic lupus erythematosus with skin involvement (n = 24) were included. The response rate was 81%, including 29 patients (60%) in complete remission and 10 (21%) in partial remission. Nine patients (19%) failed to respond. Thirteen patients (27%) developed peripheral neuropathy, which was EMG-proven in 11, including 4 patients in the 50-mg alternate-day group. Other side effects included drowsiness, constipation or abdominal pain, and amenorrhea. The relapse rate after stopping thalidomide was 67% (26/39). There was no association between a positive response to the drug and either starting doses or cumulative dose. Similarly, no association was found between peripheral neuropathy and the starting or cumulative dose.Thalidomide is effective for the treatment of severe cutaneous lupus. There were no clear dose-dependent effects. However, the high incidence of neurotoxicity, even at low doses, suggests that it may be most useful as a remission-inducing drug." @default.
• W2094973399 created "2016-06-24" @default.
• W2094973399 creator A5015749384 @default.
• W2094973399 creator A5036676754 @default.
• W2094973399 creator A5040146041 @default.
• W2094973399 creator A5043181396 @default.
• W2094973399 creator A5071375228 @default.
• W2094973399 creator A5082954659 @default.
• W2094973399 date "2005-03-01" @default.
• W2094973399 modified "2023-10-18" @default.
• W2094973399 title "Thalidomide for the treatment of resistant cutaneous lupus: Efficacy and safety of different therapeutic regimens" @default.
• W2094973399 cites W1965945408 @default.
• W2094973399 cites W1983391533 @default.
• W2094973399 cites W1985658104 @default.
• W2094973399 cites W2022943800 @default.
• W2094973399 cites W2023165227 @default.
• W2094973399 cites W2025901903 @default.
• W2094973399 cites W2030742912 @default.
• W2094973399 cites W2043046274 @default.
• W2094973399 cites W2049337843 @default.
• W2094973399 cites W2050678262 @default.
• W2094973399 cites W2057638966 @default.
• W2094973399 cites W2060662281 @default.
• W2094973399 cites W2073327254 @default.
• W2094973399 cites W2077942597 @default.
• W2094973399 cites W2091011050 @default.
• W2094973399 cites W2104613102 @default.
• W2094973399 cites W2112328159 @default.
• W2094973399 cites W2126237672 @default.
• W2094973399 cites W2138478744 @default.
• W2094973399 cites W2139609692 @default.
• W2094973399 cites W2146126581 @default.
• W2094973399 cites W2146203649 @default.
• W2094973399 cites W2159711964 @default.
• W2094973399 cites W2161590446 @default.
• W2094973399 cites W2169014127 @default.
• W2094973399 cites W2313493986 @default.
• W2094973399 cites W2336461395 @default.
• W2094973399 cites W2339981418 @default.
• W2094973399 cites W3205517494 @default.
• W2094973399 doi "https://doi.org/10.1016/j.amjmed.2004.04.030" @default.
• W2094973399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15745722" @default.
• W2094973399 hasPublicationYear "2005" @default.
• W2094973399 type Work @default.
• W2094973399 sameAs 2094973399 @default.
• W2094973399 citedByCount "78" @default.
• W2094973399 countsByYear W20949733992012 @default.
• W2094973399 countsByYear W20949733992013 @default.
• W2094973399 countsByYear W20949733992014 @default.
• W2094973399 countsByYear W20949733992015 @default.
• W2094973399 countsByYear W20949733992016 @default.
• W2094973399 countsByYear W20949733992017 @default.
• W2094973399 countsByYear W20949733992018 @default.
• W2094973399 countsByYear W20949733992019 @default.
• W2094973399 countsByYear W20949733992020 @default.
• W2094973399 countsByYear W20949733992021 @default.
• W2094973399 countsByYear W20949733992022 @default.
• W2094973399 crossrefType "journal-article" @default.
• W2094973399 hasAuthorship W2094973399A5015749384 @default.
• W2094973399 hasAuthorship W2094973399A5036676754 @default.
• W2094973399 hasAuthorship W2094973399A5040146041 @default.
• W2094973399 hasAuthorship W2094973399A5043181396 @default.
• W2094973399 hasAuthorship W2094973399A5071375228 @default.
• W2094973399 hasAuthorship W2094973399A5082954659 @default.
• W2094973399 hasConcept C126322002 @default.
• W2094973399 hasConcept C134018914 @default.
• W2094973399 hasConcept C141071460 @default.
• W2094973399 hasConcept C151032500 @default.
• W2094973399 hasConcept C159654299 @default.
• W2094973399 hasConcept C203014093 @default.
• W2094973399 hasConcept C2775915377 @default.
• W2094973399 hasConcept C2776364478 @default.
• W2094973399 hasConcept C2776694085 @default.
• W2094973399 hasConcept C2776715498 @default.
• W2094973399 hasConcept C2776755627 @default.
• W2094973399 hasConcept C2776760755 @default.
• W2094973399 hasConcept C2776912625 @default.
• W2094973399 hasConcept C2779134260 @default.
• W2094973399 hasConcept C2779609412 @default.
• W2094973399 hasConcept C2779901536 @default.
• W2094973399 hasConcept C2781059491 @default.
• W2094973399 hasConcept C555293320 @default.
• W2094973399 hasConcept C71924100 @default.
• W2094973399 hasConcept C90924648 @default.
• W2094973399 hasConceptScore W2094973399C126322002 @default.
• W2094973399 hasConceptScore W2094973399C134018914 @default.
• W2094973399 hasConceptScore W2094973399C141071460 @default.
• W2094973399 hasConceptScore W2094973399C151032500 @default.
• W2094973399 hasConceptScore W2094973399C159654299 @default.
• W2094973399 hasConceptScore W2094973399C203014093 @default.
• W2094973399 hasConceptScore W2094973399C2775915377 @default.
• W2094973399 hasConceptScore W2094973399C2776364478 @default.
• W2094973399 hasConceptScore W2094973399C2776694085 @default.
• W2094973399 hasConceptScore W2094973399C2776715498 @default.
• W2094973399 hasConceptScore W2094973399C2776755627 @default.
• W2094973399 hasConceptScore W2094973399C2776760755 @default.
• W2094973399 hasConceptScore W2094973399C2776912625 @default.
• W2094973399 hasConceptScore W2094973399C2779134260 @default.

• next